



Chair: Marija Jelusic (marija.jelusic.drazic@gmail.com) Secretary: Despina Eleftheriou (d.eleftheriou@ucl.ac.uk)

To all Vasculitis Working Party members

Dear Colleague,

Here is a short report of Vasculitis Working Party meeting that we had on June 14th, during EULAR/PReS 2019 congress in Madrid

1. Short presentation of the New Vasculitis WP Core

The New Core (according to the new PReS pillars):

- Chair:

Marija Jelusic (Univeristy of Zagreb School of Medicine, Zagreb, Croatia)

- Secretary:

Despina Eleftheriou (UCL Great Ormond St Institute of Child Health, London, UK)

- Lead of education and training:

Teresa Giani (Anna Meyer Children Hospital, Florence, Italy)

- Lead of science and research:

Ezgi Deniz Batu (Ankara Training and Research Hospital, Ankara, Turkey)

- Lead of clinical care:

Neil Martin (Royal Hospital for Children, Glasgow, Scotland)

2. EDUCATION AND TRAINING

Rolando Cimaz, Teresa Giani.

Announced the First European Congress on Kawasaki Disease EURO – KiDs Congress 2020, July 7-8th 2020, Paris, France

A first event in Europe!

A half-day workshop: "Kawasaki disease, autoinflammation and beyond" aimed to gather experiences on new treatment targets, biomarkers, and integrated research strategies.

A two-day main meeting aimed to update on clinical innovation, recommendations, basic science, and sharing clinical experiences.

3. SCIENCE AND RESEARCH - PROPOSALS FOR THE PROJECTS

3A. PReS/PRINTO Research projects

From this year an annual call for projects from the WPs have been founded by PReS/PRINTO collaboration. Funds will consist of 10,000/year (total 30,000) in cash provided by PReS, and of an equivalent amount in manpower for implementation and infrastructure provided by PRINTO.

Each PReS/PRINTO grant will be funded for a maximum of 3 years. Proposals will be peer reviewed by members of the PReS Council and members of the Advisory Council of PRINTO.

2019: deadline for submission September 30, 2019; 2020: deadline for submission April 30, 2020.

Granted projects and updates will be presented at Annual PReS Meeting in a session dedicated to the Research of the Wps. Detailed info will be available on PReS and PRINTO websites

3B. Seza Ozen: Comparison of pediatric criteria with adult classification criteria in granulomatosis with polyangiitis

- Multicentre study, at least 2 patients with GPA per center, and 2 controls (patients with other primary systemic vasculitis or mimicks such as sarcoidosis) per 1 GPA patient

For further information please contact: PI – Seza Ozen (sezaozen@gmail.com)

- 3C. Despina Eleftheriou: KD-CAAP study "Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms in Kawasaki disease."
- This will be a multicentre European study (funding already approved) to establish the efficacy and safety of added corticosteroids to IVIG and aspirin for treatment of KD.
- We are aiming to recruit 262 children over 30 months from around 40 centres in 12 countries.

Chief Investigators: Despina Eleftheriou (d.eleftheriou@ucl.ac.uk), and Paul Brogan (p.brogan@ucl.ac.uk)

3D. Marija Jelusic: Histological predictors of outcome in patients with Henoch-Schonlein purpura and nephritis

Primary aims of the study:

- To compare the ISKDC, Haas, Oxford and modified semiquantitative classification (SQC) for their ability to predict the clinical outcomes in HSP
- To validate the feasibility of the SQC, Oxford classification, and Haas classification,
- To establish which variables of each histological classification most significantly predict renal outcome/have the strongest association with unfavorable outcome *Patients and methods:*
- A multicenter, multinational study, patients aged < 18 years at the time of diagnosis with biopsy-proven HSPN (patients' medical records and appropriate histology material for re-analyses + newly diagnosed pediatric patients)
- biopsy material reviewed and/or scored by according to ISKDC, Oxford, Haas and SQC classification by an experienced renal pathologist, blinded to the patients' medical histories and laboratory results.

PROGRESS

<u>Published paper:</u> Jelusic M, Sestan M, Cimaz R, Ozen S. Different histological classification in HSPN: which one should be used. Pediatr Rheumatol Online J 2019;17:10

For further information please contact PI - Marija Jelusic (marija.jelusic.drazic@gmail.com)

Sincerely yours

Marija Jelusic, Chair of Vasculitis WP

Despina Eleftheriou, Secretary of the Vasculitis WP